Skip to main content
P. Leif Bergsagel on Muck Rack

P. Leif Bergsagel

Phoenix
As seen in: Nature, The Journal of Clinical Investigation
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with P. Leif

Contact P. Leif, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10–49 years of age: a population-based study from the National Health and Nutritional Examination Survey

|
By Shaji Kumar Verified, David Murray, Dirk R. Larson, Ola Landgren, P. Leif Bergsagel, James R. Cerhan, S. Vincent Rajkumar
| Nature Verified
Abstract The prevalence of monoclonal gammopathy of undetermined significance (MGUS) increases with age, but the study of age of onset and the prevalence of MGUS in younger individuals has been limited by lack of sensitive serum protein testing methods. In addition, there is marked racial disparity in the prevalence in Black individuals compared with White individuals and it is important to determine if MGUS has an earlier age of onset in Black individuals.
Open in Who Shared Issue with article?

Proteomic profiling revealed unique disease biology associated with 1q abnormalities in multiple myeloma

|
By Kiran K. Mangalaparthi, Joel-Sean Hsu, J. Erin Wiedmeier-Nutor, Partho Sen, Julie Cadwallader Staub, Firdous A. Bhat, Caleb Stein, Greg J. Ahmann, Shaji Kumar Verified, S. Vincent Rajkumar, P. Leif Bergsagel, Rafael Fonseca, Esteban Braggio, Richard K. Kandasamy, Akhilesh Pandey
| Nature Verified
Abstract Gain or amplification of chromosome 1q (+1q) is a common genomic alteration occurring in the plasma cells in nearly 40% of multiple myeloma patients. Although it is associated with inferior outcomes and is more common in the relapsed or refractory stages, the impact of +1q at the proteomic level remains unclear. Here, we studied enriched CD138+ plasma cells in newly diagnosed multiple myeloma to uncover molecular alterations associated with +1q.
Open in Who Shared Issue with article?

A single next generation sequencing assay for detection of driver mutations, rearrangements and copy number abnormalities in plasma cell dyscrasias

|
By Daniela Berrio Trujillo, James B. Smadbeck, Mariano Arribas, Hongwei Tang, Neeraj Sharma, Shaji Kumar Verified, A. Stewart, Rafael Fonseca, P. Leif Bergsagel, Yan W Asmann, Linda B. Baughn, Esteban Braggio, Cecilia Bonolo de Campos, Gregory J. Ahmann
| Nature Verified
Multiple myeloma (MM) is a plasma cell malignancy characterized by recurring primary and secondary genetic abnormalities that impact clinical outcome and response to therapy.
Open in Who Shared Issue with article?
See all 21 articles